Tumor suppressor MicroRNA-493 decreases cell motility and migration ability in human bladder cancer cells by downregulating RhoC and FZD4

Molecular Cancer Therapeutics

Volumn 11, Issue 1, 2012, Pages 244-253

  Ueno, Koji ^a   Hirata, Hiroshi ^a   Majid, Shahana ^a   Yamamura, Soichiro ^a   Shahryari, Varahram ^a   Tabatabai, Z Laura ^a   Hinoda, Yuji ^b   Dahiya, Rajvir ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FRIZZLED PROTEIN; LUCIFERASE; MICRORNA; MICRORNA 493; RHO KINASE; RNA; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER TISSUE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE TARGETING; GENETIC ALGORITHM; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROARRAY ANALYSIS; ONCOGENE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

3' UNTRANSLATED REGIONS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DOWN-REGULATION; FRIZZLED RECEPTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MICRORNAS; RHO GTP-BINDING PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; URINARY BLADDER NEOPLASMS;

EID: 84855678649     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0592     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Pollard C, Smith SC, Theodorescu D. Molecular genesis of nonmuscle- invasive urothelial carcinoma (NMIUC). Expert Rev Mol Med 2010;12:e10.
3. Proctor I, Stoeber K, Williams GH. Biomarkers in bladder cancer. Histopathology 2010;57:1-13.
4. Pasin E, Josephson DY, Mitra AP, Cote RJ, Stein JP. Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol 2008;10:31-43.
5. Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU Guidelines. Eur Urol 2011;59: 1009-18.
6. Liebert M, Seigne J. Characteristics of invasive bladder cancers: histological and molecular markers. Semin Urol Oncol 1996;14: 62-72. (Pubitemid 26154973)
7. Wallerand H, Reiter RR, Ravaud A. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways. Curr Opin Urol 2008;18:524-32.
8. Netto GJ, Epstein JI. Theranostic and prognostic biomarkers: genomic applications in urological malignancies. Pathology 2010; 42:384-94.
9. Ying SY, Chang DC, Lin SL. The microRNA (miRNA): overview of the RNA genes that modulate gene function. Mol Biotechnol 2008;38: 257-68.
10. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002;3:737-47.
11. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 2007;25:387-92. (Pubitemid 47362758)
12. Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer 2009;125:345-52.
13. Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, Palazzo JP, et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 2009;219:214-21.
14. Dyrskjøt L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 2009;69:4851-60.
15. Huang L, Luo J, Cai Q, Pan Q, Zeng H, Guo Z, et al. MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. Int J Cancer 2011;128:1758-69.
16. Ueno K, Hirata H, Shahryari V, Chen Y, Zaman MS, Singh K, et al. Tumour suppressor microRNA-584 directly targets oncogene Rock-1 and decreases invasion ability in human clear cell renal cell carcinoma. Br J Cancer 2011;104:308-15.
17. Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y, et al. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 2003;9:2632-41. (Pubitemid 36842107)
18. Wang W, Wu F, Fang F, Tao Y, Yang L. Inhibition of invasion and metastasis of hepatocellular carcinoma cells via targeting RhoC in vitro and in vivo. Clin Cancer Res 2008;14:6804-12.
19. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000;406: 532-5. (Pubitemid 30625739)
20. HakemA, Sanchez-Sweatman O, You-Ten A, Duncan G, Wakeham A, Khokha R, et al. RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev 2005;19:1974-9. (Pubitemid 41247955)
21. Ikoma T, Takahashi T, Nagano S, Li YM, Ohno Y, Ando K, et al. A definitive role of RhoC in metastasis of orthotopic lung cancer in mice. Clin Cancer Res 2004;10:1192-200.
22. Faried A, Faried LS, Kimura H, Nakajima M, Sohda M, Miyazaki T, et al. RhoA and RhoC proteins promote both cell proliferation and cell invasion of human oesophageal squamous cell carcinoma cell lines in vitro and in vivo. Eur J Cancer 2006;42:1455-65.
23. Iiizumi M, Bandyopadhyay S, Pai SK, Watabe M, Hirota S, Hosobe S, et al. RhoC promotes metastasis via activation of the Pyk2 pathway in prostate cancer. Cancer Res 2008;68:7613-20.
24. Islam M, Lin G, Brenner JC, Pan Q, Merajver SD, Hou Y, et al. RhoC expression and head and neck cancer metastasis. Mol Cancer Res 2009;7:1771-80.
25. Wang W, Yang LY, Huang GW, Lu WQ, Yang ZL, Yang JQ, et al. Genomic analysis reveals RhoC as a potential marker in hepatocellular carcinoma with poor prognosis. Br J Cancer 2004; 90:2349-55. (Pubitemid 38961899)
26. Horiuchi A, Imai T, Wang C, Ohira S, Feng Y, Nikaido T, et al. Upregulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 2003;83:861-70. (Pubitemid 36723695)
27. Suwa H, Ohshio G, Imamura T, Watanabe G, Arii S, Imamura M, et al. Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer 1998;77:147-52. (Pubitemid 28029787)
28. Jiang L, Liu X, Kolokythas A, Yu J, Wang A, Heidbreder CE, et al. Downregulation of the Rho GTPase signaling pathway is involved in the microRNA-138-mediated inhibition of cell migration and invasion in tongue squamous cell carcinoma. Int J Cancer 2010; 127:505-12.
29. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and betacatenin signalling: diseases and therapies. Nat Rev Genet 2004;5: 691-701. (Pubitemid 39150127)
30. Ahmad I, Patel R, Liu Y, Singh LB, Taketo MM, Wu XR, et al. Ras mutation cooperates with b-catenin activation to drive bladder tumourigenesis. Cell Death Dis 2011;2:e124.